Search - tctmd.com

Displaying 621 - 640 of 1464

Sort: Relevancy | Date

Complete Revascularization Benefits May Be Due to Stenting Vulnerable Plaques

News Conference News AHA 2019

Complete Revascularization Benefits May Be Due to Stenting Vulnerable Plaques

November 21, 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

News Conference News AHA 2019

Inclisiran in FH: Safe, Cuts LDL in This Challenging Group

Yael L. Maxwell

November 19, 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

November 18, 2019

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

News Conference News AHA 2019

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

November 18, 2019

Effect of Icosapent Ethyl on progression of coronary atherosclerosis in patients with elevated triglycerideson statin therapy: the EVAPORATE study

Presentation AHA 2019

Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients With Elevated Triglycerides on Statin Therapy: The EVAPORATE Study

Presenter: Matthew Budoff

November 18, 2019

No Benefit of Colchicine in All-Comers PCI

News Conference News AHA 2019

No Benefit of Colchicine in All-Comers PCI

November 17, 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

News Conference News AHA 2019

Inclisiran Slashes LDL in ASCVD Patients: ORION-10

Yael L. Maxwell

November 16, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

November 16, 2019

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

News Conference News AHA 2019

LDL Levels Still Too High in Many Statin-Treated Patients: PINNACLE

Michael O'Riordan

November 13, 2019

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

News Daily News

Lipid Levels Declining in US, With Drops Seen After 2013 Guideline Release

Michael O'Riordan

November 11, 2019

Noninvasive Tests for Chest Pain: New Insight Into Who Benefits Most

News Daily News

Noninvasive Tests for Chest Pain: New Insight Into Who Benefits Most

Yael L. Maxwell

November 07, 2019

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

News Daily News

Vasospasm, Microvascular Dysfunction Tied to MACE in Nonobstructive CAD

Michael O'Riordan

November 05, 2019

CMS Finalizes Rule Allowing Reimbursement of PCI in Ambulatory Centers

News Daily News

CMS Finalizes Rule Allowing Reimbursement of PCI in Ambulatory Centers

November 04, 2019

Women More Likely Than Men to Develop Heart Failure After STEMI

News Daily News

Women More Likely Than Men to Develop Heart Failure After STEMI

November 04, 2019

Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD

News Daily News

Troponin Increases After Elective PCI Tied to Complexity, Extent of CAD

October 29, 2019

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

News Daily News

Evolocumab Safe and Effective Out to 5 Years: OSLER-1

Yael L. Maxwell

October 22, 2019

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

News Daily News

New Review Questions Statin Benefit in Lower-Risk Primary Prevention Patients

Michael O'Riordan

October 22, 2019

Elderly Women Worse Off Than Men Before and After Acute MI

News Daily News

Elderly Women Worse Off Than Men Before and After Acute MI

Yael L. Maxwell

October 22, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.